Delving into the Latest Updates on Seletracetam with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2S)-2-((4S)-4-(2,2-Difluoroethenyl)-2-oxopyrrolidin-1-yl)butanamide, Seletracetam (USAN/INN)

+ [4]

Target

SV2A

Action

modulators

Mechanism

SV2A modulators(Synaptic vesicle glycoprotein 2A modulators)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Acute repetitive seizure

Inactive Indication

Drug Resistant EpilepsyEpilepsies, Partial

Originator Organization

UCB SA

Active Organization

Prevep, Inc.

Inactive Organization

UCB Pharma SA

UCB Pharma GmbH

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H14F2N2O2

InChIKeyANWPENAPCIFDSZ-RQJHMYQMSA-N

CAS Registry357336-74-4

The objective of this study was to evaluate the effect of seletracetam (SEL), a potent modulator of synaptic vesicle glycoprotein 2A (SV2A), in patients with photoparoxysmal EEG response (PPR) to intermittent photic stimulation (IPS) as proof-of-principle of efficacy in patients with epilepsy. In this multicenter, single-blind Phase II study, adults with photosensitive epilepsy, with/without concomitant antiseizure medication therapy, underwent IPS under 3 eye conditions (at eye closure, eyes closed and eyes open) after a single oral dose of placebo (day - 1) or SEL (day 1; 0.5, 1, 2, 4, 10, or 20 mg). Complete suppression was a standardized photosensitivity range reduction to 0 over ≥ 1 time points for all eye conditions. Partial suppression was a ≥ 3-point reduction over ≥ 3 testing times vs the same time points on day - 1 in ≥ 1 eye condition. In addition, pharmacokinetics and safety were assessed. Of 27 evaluable patients, 9 reentered to receive a 2nd dosing 1-6 months later, providing a total of 36 individual exposures. At all doses administered - even the lowest -, several subjects reached a complete abolishment of PPR, with a rapid onset of effect. Overall, complete abolishment of PPR was obtained in 40-71 % of the patients; the effect increasing with the dose. In terms of effective doses to suppress PPR, SEL was at least 1,500 times more potent than levetiracetam and 10-20 times more potent than brivaracetam. Adverse events of SEL, including dizziness and somnolence, were mild to moderate. Pharmacokinetics of SEL demonstrated rapid absorption and a linear dose:plasma level relationship. This proof-of-principle study demonstrates that - based on our own experience - SEL is the most potent compound ever tested in the photosensitivity model.

14 Nov 2022·Angewandte Chemie International Edition

Nickel‐Catalyzed Defluorinative Asymmetric Cyclization of Fluoroalkyl‐Substituted 1,6‐Enynes for the Synthesis of Seletracetam

Article

Author: Wang, Kuai ; Liu, Wenfeng ; Kong, Wangqing ; Chen, Jiachang

AbstractThe introduction of fluorine‐containing groups into organic molecules can significantly affect their physical and chemical properties and has long been used as an effective strategy for drug discovery and development. Consequently, the development of catalytic asymmetric methods for the synthesis of fluorine‐containing heterocycles is highly desirable and sought after. Herein, we describe a nickel‐catalyzed defluorinative asymmetric cyclization of fluoroalkyl‐substituted 1,6‐enynes, providing an expedient access to synthetically attractive 4‐fluorovinyl‐substituted 2‐pyrrolidones in good yields with remarkable high levels of chemo‐, regio‐, and enantioselectivities (90–99 % ee,>35 examples). This protocol features readily available starting materials and excellent functional group compatibility, and exhibits complementary regioselectivity. The utility of this strategy was demonstrated in the enantioselective synthesis of the antiepileptic drug Seletracetam.

01 Jan 2022·Chinese Journal of Organic Chemistry

Nickel-Catalyzed Defluorinative Asymmetric Cyclization of Fluoroalkyl-Substituted 1,6-Enynes for the Synthesis of Seletracetam

Author: Lin, Quan ; Gong, Hegui

The paper introduced a nickel-catalyzed defluorinated asym. arylation cyclization reaction of fluoroalkyl substituted 1,6-ene alkyne, which can synthesize a variety of attractive 4-fluoroalkyl substituted 2-pyrrolidone with excellent chem. selectivity, regional selectivity and enantioselectivity.The process had mild reaction conditions, good functional group compatibility, obvious advantages of gram-level reaction and further transformation, and broad application prospects.

100 Deals associated with Seletracetam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05817	Seletracetam	-	DB05885

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsies, Partial	Phase 2	-	UCB Pharma GmbH	01 May 2008
Epilepsies, Partial	Phase 2	-	UCB Pharma GmbH	01 May 2008
Drug Resistant Epilepsy	Phase 2	-	UCB Pharma GmbH	01 Feb 2006
Drug Resistant Epilepsy	Phase 2	-	UCB Pharma GmbH	01 Feb 2006
Seizures	Phase 2	United States	UCB Pharma SA	31 Aug 2005
Seizures	Phase 2	Canada	UCB Pharma SA	31 Aug 2005
Acute repetitive seizure	Preclinical	United States	Prevep, Inc.	01 Feb 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00152451 (CTgov)	Phase 2	Epilepsies, Partial \| Drug Resistant Epilepsy	31	Seletracetam (ucb 44212)	tdgliziegi(almddayycj) = yidvxkajpk xvacijkfzu (sbwqmwqcvv, muinswxpmy - kvfhhsevpa) View more	-	29 Mar 2024
NCT00152503 (CTgov)	Phase 2	Seizures \| Epilepsies, Partial \| Drug Resistant Epilepsy	59	Seletracetam (UCB44212)	mpfubgipar(rjpbienrun) = ywqtedqzvw ukryriscxu (yfdwcldwji, bzcgiiqspb - esulhaivoj) View more	-	07 Sep 2023